On December 9th, Gelonghui reported that wuhan keqian biology co.,ltd (688526.SH) announced that to enhance the company's market competitiveness and accelerate development in the biological product industry, thereby better improving the company's brand influence and core competitiveness, according to the "Company Articles of Association", "Cooperative Research and Development Management System" and other regulations, after competitive negotiations with Huazhong Agricultural University, it has obtained the following projects for cooperative research and development: infectious bronchitis in chickens (Type A + Type B + Type C, recombinant protein), mycoplasma gallisepticum, the three-inactivated vaccine for avian pathogenic mycoplasmosis (HB03 strain + HB15 strain), recombinant Newcastle disease virus, infectious bronchitis virus, bird flu virus (H9 subtype), recombinant virus for infectious bursal disease, avian adenoviruses (Group I, Type 4) five-inactivated vaccine (VIIXF strain + rRBD protein + JS strain + WF strain + HB-2 strain), the three-inactivated vaccines for mycoplasma gallisepticum, avian pathogenic mycoplasmosis, and infectious bronchitis, the four-inactivated vaccines for duck paramyxovirus disease, bird flu (H9 subtype), duck Tembusu virus disease, and duck adenovirus disease (Type 3) (AN20 strain + HB19 strain + DF2 strain + rFiber2), the two-inactivated vaccines for mycoplasma gallisepticum and avian pathogenic mycoplasmosis, and the two-live vaccines for novel duck enterovirus and duck Tembusu virus. It is now planned to sign a joint cooperation research and development agreement with Huazhong Agricultural University for these six projects. Among them, for the project of infectious bronchitis in chickens (Type A + Type B + Type C, recombinant protein), mycoplasma gallisepticum, and the three-inactivated vaccine for avian pathogenic mycoplasmosis (HB03 strain + HB15 strain), the company plans to pay Huazhong Agricultural University 0.7 million yuan; for the project of recombinant Newcastle disease virus, infectious bronchitis virus, bird flu virus (H9 subtype), recombinant virus for infectious bursal disease, and avian adenoviruses (Group I, Type 4) five-inactivated vaccine (VIIXF strain + rRBD protein + JS strain + WF strain + HB-2 strain), the company plans to pay Huazhong Agricultural University 1.5 million yuan; for the project of mycoplasma gallisepticum, avian pathogenic mycoplasmosis, and infectious bronchitis three-inactivated vaccine, the company plans to pay Huazhong Agricultural University 1 million yuan; for the project of duck paramyxovirus disease, bird flu (H9 subtype), duck Tembusu virus disease, and duck adenovirus disease (Type 3) four-inactivated vaccine (AN20 strain + HB19 strain + DF2 strain + rFiber2), the company plans to pay Huazhong Agricultural University 1.5 million yuan; for the project of mycoplasma gallisepticum and avian pathogenic mycoplasmosis two-inactivated vaccine, the company plans to pay Huazhong Agricultural University 0.5 million yuan; for the project of the novel duck enterovirus and duck Tembusu virus two-live vaccine, the company plans to pay Huazhong Agricultural University 0.6 million yuan. The total payment to Huazhong Agricultural University for the above six projects amounts to 5.8 million yuan.